Product Center
Our company's technological and industrial innovation capabilities continue to be recognized
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-01-09
- Views:
(Summary description)Recently, the company has successively obtained two important certifications: "High tech Enterprise" and "Jiangsu Provincial Industrial Technology Engineering Center for Human Vaccine Technology Innovation (preparatory)", which have been officially approved by the Jiangsu Provincial High tech Enterprise Certification Management Coordination Group and the Jiangsu Provincial Development and Reform Commission, respectively. This marks the comprehensive strength of the company in technological innovation and industrial transformation, which has gained authoritative recognition.
Our company's technological and industrial innovation capabilities continue to be recognized
(Summary description)Recently, the company has successively obtained two important certifications: "High tech Enterprise" and "Jiangsu Provincial Industrial Technology Engineering Center for Human Vaccine Technology Innovation (preparatory)", which have been officially approved by the Jiangsu Provincial High tech Enterprise Certification Management Coordination Group and the Jiangsu Provincial Development and Reform Commission, respectively. This marks the comprehensive strength of the company in technological innovation and industrial transformation, which has gained authoritative recognition.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-01-09 09:07
- Views:
Recently, the company has successively obtained two important certifications: "High tech Enterprise" and "Jiangsu Provincial Industrial Technology Engineering Center for Human Vaccine Technology Innovation (preparatory)", which have been officially approved by the Jiangsu Provincial High tech Enterprise Certification Management Coordination Group and the Jiangsu Provincial Development and Reform Commission, respectively. This marks the comprehensive strength of the company in technological innovation and industrial transformation, which has gained authoritative recognition.
Innovation of Human Vaccine Technology Jiangsu Provincial Industrial Technology Engineering Center (under construction)
High tech enterprises are jointly evaluated and recognized by the Ministry of Science and Technology, the Ministry of Finance, and the State Administration of Taxation, with the aim of selecting and supporting enterprises that continue to conduct research and development and technology transfer in key high-tech fields supported by the state, and form core independent intellectual property rights. The certification standards and recognition procedures for high-tech enterprises are strict, with core independent intellectual property rights, scientific and technological achievement transformation ability, research and development organizational management level, and enterprise growth as the main assessment indicators. It is one of the most important and widely recognized national honors for Chinese technology enterprises.
The center will focus on the key technologies of vaccine research and industrialization in the development of the biological products industry in Jiangsu Province, targeting major infectious diseases such as influenza, chickenpox and shingles, respiratory syncytial virus, monkeypox, etc., to carry out the research and industrialization of new human vaccines. By utilizing AI technology to empower the entire process of vaccine design and development, anchoring international standards, breaking through key technologies such as large-scale virus cultivation and purification, mRNA vaccine preparation, and novel adjuvants, we aim to build advanced research and development platforms for large-scale virus amplification and purification, mRNA vaccines, novel vaccine adjuvants, and micro immunization research. Embrace the wave of intelligence and promote the upgrading of research and development work towards intelligence, precision, and efficiency.
The deep integration of technological innovation and industrial innovation is the core driving force for the company's development. In recent years, the company has continuously increased its investment in innovative research and talent development, and has made breakthroughs in platform and team building. It has been awarded multiple certifications such as "Jiangsu Postdoctoral Innovation Practice Base", "Taizhou Human Vaccine Engineering Research Center", and "Taizhou Innovative Virus Vaccine Engineering Technology Research Center"; The innovative talent team has also received recognition, including support from the National Key Talent Project Class A Talents and the Taizhou 113 Leading Talent Team Project.
The approval of the "Jiangsu Provincial Industrial Technology Engineering Center for Human Vaccine Technology Innovation (preparatory)" and the recognition as a "National High tech Enterprise" is an important manifestation of the company's commitment to the deep integration of scientific and technological innovation and industrial innovation. They not only signify our authoritative recognition of our full chain innovation capabilities in technology research and development, engineering scaling up, and industrialization landing, but also demonstrate our systematic layout of transforming cutting-edge technology into industrial strength. In the future, we will continue to promote the dual empowerment of technological breakthroughs and industrial applications, laying a solid foundation for innovation in the company's development. Based on the industrial ecology of China Medical City, we will contribute Zhonghui's strength to the high-quality development of Taizhou's pharmaceutical industry!
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
